A U.S. cannabis company has expressed interest in acquiring Aurora Cannabis Inc., based in Edmonton. Aurora revealed that it will form a special committee to review the unsolicited offer from Curaleaf Holdings Inc., aiming to purchase all shares of the company.
Curaleaf, headquartered in Stamford, Conn., shared its plan to create a combined cannabis entity operating in 17 countries across Europe, North America, and other global markets. Despite attempts to negotiate privately with Aurora, Curaleaf decided to make its bid public after facing reluctance from Aurora’s board to engage in discussions.
Curaleaf proposed a payment of $4 US per share to Aurora shareholders, along with an additional $0.75 US cash for each share. Aurora confirmed receiving letters from Curaleaf outlining the acquisition proposals but disputed Curaleaf’s claim that it declined to engage with the offer.
Aurora stated that its lead independent director had communicated with Curaleaf’s CEO as recently as July 24 and expressed a willingness to continue dialogues. The Canadian company will establish a special committee of independent directors to evaluate the proposal’s alignment with stakeholders’ interests.
Acknowledging Curaleaf’s interest, Aurora emphasized that the current offer undervalues its long-term potential. TD Cowen analysts Derek Lessard and Ryan Neal highlighted Aurora’s market leadership, product portfolio, financial strength, and regulatory capabilities, suggesting that the proposed consideration does not fully reflect Aurora’s intrinsic value.
Curaleaf’s CEO emphasized that merging the companies would leverage Curaleaf’s global distribution network with Aurora’s international medical cannabis presence and manufacturing capabilities. The combined revenue of the two companies exceeded $1.5 billion US in the past year, with Curaleaf anticipating annual cost synergies of at least $40 million US from the potential takeover.
The merger, according to Jordan, offers a mutually beneficial opportunity for shareholders of both companies to access a more diversified global platform and capitalize on regulatory developments in the U.S.
